The current strategy for interrupting transmission of lymphatic filariasis (LF) is annual mass drug administration (MDA), at good coverage, for 6 or more years. We describe our programmatic experience delivering the MDA combination of ivermectin and albendazole in Plateau and Nasarawa states in central Nigeria, where LF is caused by anopheline transmitted Wuchereria bancrofti. Baseline LF mapping using rapid blood antigen detection tests showed mean local government area (LGA) prevalence of 23% (range 4–62%). MDA was launched in 2000 and by 2003 had been scaled up to full geographic coverage in all 30 LGAs in the two states; over 26 million cumulative directly observed treatments were provided by community drug distributors over the intervention period. Reported treatment coverage for each round was ≥85% of the treatment eligible population of 3.7 million, although a population-based coverage survey in 2003 showed lower coverage (72.2%; 95% CI 65.5–79.0%). To determine impact on transmission, we monitored three LF infection parameters (microfilaremia, antigenemia, and mosquito infection) in 10 sentinel villages (SVs) serially. The last monitoring was done in 2009, when SVs had been treated for 7–10 years. Microfilaremia in 2009 decreased by 83% from baseline (from 4.9% to 0.8%); antigenemia by 67% (from 21.6% to 7.2%); mosquito infection rate (all larval stages) by 86% (from 3.1% to 0.4%); and mosquito infectivity rate (L3 stages) by 76% (from 1.3% to 0.3%). All changes were statistically significant. Results suggest that LF transmission has been interrupted in 5 of the 10 SVs, based on 2009 finding of microfilaremia ≥1% and/or L3 stages in mosquitoes. Four of the five SVs where transmission persists had baseline antigenemia prevalence of >25%. Longer or additional interventions (e.g., more frequent MDA treatments, insecticidal bed nets) should be considered for ‘hot spots’ where transmission is ongoing.
References
[1]
(1984) Lymphatic filariasis. Fourth report of the WHO Expert Committee on Filariasis. World Health Organ Tech Rep Ser 702: 3–112. doi: 10.1177/146642408510500317
[2]
(2006) Preventative chemotherapy in human helminthiasis. Coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers. World Health Organization.
[3]
(1999) Guidelines for certifying lymphatic filariasis elimination (including discussion of critical issues and rationale). World Health Organization.
[4]
Molyneux DH, Zagaria N (2002) Lymphatic filariasis elimination: progress in global programme development. Ann Trop Med Parasitol 96: Suppl 2S15–40. doi: 10.1179/000349802125002374
[5]
Ottesen EA (2006) Lymphatic filariasis: Treatment, control and elimination. Adv Parasitol 61: 395–441. doi: 10.1016/S0065-308X(05)61010-X
[6]
(2010) Global programme to eliminate lymphatic filariasis. Wkly Epidemiol Rec 85: 365–372.
[7]
Organization WH (2011) Progress Report 2000–2009 and Strategic Plan 2010–2020 of the Global Programme to Eliminate Lymphatic Filariasis.
[8]
Gyapong JO, Kumaraswami V, Biswas G, Ottesen EA (2005) Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert Opin Pharmacother 6: 179–200. doi: 10.1517/14656566.6.2.179
[9]
(1993) Recommendations of the International Task Force for Disease Eradication. MMWR Recomm Rep 42: 1–38.
[10]
(1999) Building Partnerships for Lymphatic Filariasis. 64 p. Strategic Plan. World Health Organization.
[11]
(2008) Global programme to eliminate lymphatic filariasis. Wkly Epidemiol Rec 83: 333–341.
[12]
Michael E, Malecela-Lazaro MN, Simonsen PE, Pedersen EM, Barker G, et al. (2004) Mathematical modelling and the control of lymphatic filariasis. Lancet Infect Dis 4: 223–234. doi: 10.1016/S1473-3099(04)00973-9
[13]
(2005) Sixth meeting of the Technical Advisory Group on the Global Elimination of Lymphatic Filariasis, Geneva, Switzerland, 20–23 September 2005. Wkly Epidemiol Rec 80: 401–408.
[14]
Gyapong JO, Twum-Danso NA (2006) Editorial: Global elimination of lymphatic filariasis: fact or fantasy? Trop Med Int Health 11: 125–128. doi: 10.1111/j.1365-3156.2005.01542.x
[15]
Kyelem D, Biswas G, Bockarie MJ, Bradley MH, El-Setouhy M, et al. (2008) Determinants of success in national programs to eliminate lymphatic filariasis: a perspective identifying essential elements and research needs. Am J Trop Med Hyg 79: 480–484.
[16]
Simonsen PE, Pedersen EM, Rwegoshora RT, Malecela MN, Derua YA, et al. (2010) Lymphatic filariasis control in Tanzania: effect of repeated mass drug administration with ivermectin and albendazole on infection and transmission. PLoS Negl Trop Dis 4: e696. doi: 10.1371/journal.pntd.0000696
[17]
(2000) Preparing and implementing a national plan to eliminate lymphatic filariasis. Geneva: World Health Organization.: World Health Organization.
[18]
(2005) Monitoring and epidemiological assessment of the programme to eliminate lymphatic filariasis at implementation unit level. World Health Organization.
[19]
Lindsay SW, Thomas CJ (2000) Mapping and estimating the population at risk from lymphatic filariasis in Africa. Trans R Soc Trop Med Hyg 94: 37–45. doi: 10.1016/S0035-9203(00)90431-0
[20]
Njepuome NA, Hopkins DR, Richards FO Jr, Anagbogu IN, Pearce PO, et al. (2009) Nigeria's war on terror: fighting dracunculiasis, onchocerciasis, lymphatic filariasis, and schistosomiasis at the grassroots. Am J Trop Med Hyg 80: 691–698.
[21]
Miri ES, Hopkins DR, Ruiz-Tiben E, Keana AS, Withers PC Jr, et al. (2010) Nigeria's triumph: dracunculiasis eradicated. Am J Trop Med Hyg 83: 215–225. doi: 10.4269/ajtmh.2010.10-0140
[22]
(2010) African Programme for Onchocerciasis Control - report of the sixth meeting of national task forces, October 2009. Wkly Epidemiol Rec 85: 23–28.
[23]
Richards F Jr, Gonzales-Peralta C, Jallah E, Miri E (1996) Community-based ivermectin distributors: onchocerciasis control at the village level in Plateau State, Nigeria. Acta Trop 61: 137–144. doi: 10.1016/0001-706X(95)00116-V
[24]
Miri ES (1998) Problems and perspectives of managing an onchocerciasis control programme: a case study from Plateau state, Nigeria. Ann Trop Med Parasitol 92: Suppl 1S121–128. doi: 10.1080/00034989859654
[25]
Gemade EI, Jiya JY, Nwoke BE, Ogunba EO, Edeghere H, et al. (1998) Human onchocerciasis: current assessment of the disease burden in Nigeria by rapid epidemiological mapping. Ann Trop Med Parasitol 92: Suppl 1S79–83. doi: 10.1080/00034989859609
[26]
Hopkins DR, Eigege A, Miri ES, Gontor I, Ogah G, et al. (2002) Lymphatic filariasis elimination and schistosomiasis control in combination with onchocerciasis control in Nigeria. Am J Trop Med Hyg 67: 266–272.
[27]
Richards FO Jr, Eigege A, Pam D, Kal A, Lenhart A, et al. (2005) Mass ivermectin treatment for onchocerciasis: lack of evidence for collateral impact on transmission of Wuchereria bancrofti in areas of co-endemicity. Filaria J 4: 6. doi: 10.1186/1475-2883-4-6
[28]
Richards FO Jr, Pam DD, Kal A, Gerlong GY, Onyeka J, et al. (2005) Significant decrease in the prevalence of Wuchereria bancrofti infection in anopheline mosquitoes following the addition of albendazole to annual, ivermectin-based, mass treatments in Nigeria. Ann Trop Med Parasitol 99: 155–164. doi: 10.1179/136485905X19838
[29]
Weil GJ, Ramzy RM (2007) Diagnostic tools for filariasis elimination programs. Trends Parasitol 23: 78–82. doi: 10.1016/j.pt.2006.12.001
[30]
Eigege A, Richards FO Jr, Blaney DD, Miri ES, Gontor I, et al. (2003) Rapid assessment for lymphatic filariasis in central Nigeria: a comparison of the immunochromatographic card test and hydrocele rates in an area of high endemicity. Am J Trop Med Hyg 68: 643–646.
[31]
(2000) Operational guidelines for rapid mapping of Bancroftian filariasis in Africa. World Health Organization.
[32]
Weil GJ, Lammie PJ, Weiss N (1997) The ICT Filariasis Test: A rapid-format antigen test for diagnosis of bancroftian filariasis. Parasitol Today 13: 401–404. doi: 10.1016/S0169-4758(97)01130-7
[33]
Amazigo UV, Brieger WR, Katabarwa M, Akogun O, Ntep M, et al. (2002) The challenges of community-directed treatment with ivermectin (CDTI) within the African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol 96: Suppl 1S41–58. doi: 10.1179/000349802125000646
[34]
Amazigo U (2008) The African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol 102: Suppl 119–22. doi: 10.1179/136485908X337436
[35]
Terranella A, Eigiege A, Gontor I, Dagwa P, Damishi S, et al. (2006) Urban lymphatic filariasis in central Nigeria. Ann Trop Med Parasitol 100: 163–172. doi: 10.1179/136485906X86266
[36]
Richards FO Jr, Miri ES, Katabarwa M, Eyamba A, Sauerbrey M, et al. (2001) The Carter Center's assistance to river blindness control programs: establishing treatment objectives and goals for monitoring ivermectin delivery systems on two continents. Am J Trop Med Hyg 65: 108–114.
[37]
Farid HA, Morsy ZS, Helmy H, Ramzy RM, El Setouhy M, et al. (2007) A critical appraisal of molecular xenomonitoring as a tool for assessing progress toward elimination of Lymphatic Filariasis. Am J Trop Med Hyg 77: 593–600.
[38]
McLaughlin SI, Radday J, Michel MC, Addiss DG, Beach MJ, et al. (2003) Frequency, severity, and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole in Leogane, Haiti, 2000. Am J Trop Med Hyg 68: 568–573.
[39]
Grady CA, de Rochars MB, Direny AN, Orelus JN, Wendt J, et al. (2007) Endpoints for lymphatic filariasis programs. Emerg Infect Dis 13: 608–610. doi: 10.3201/eid1304.061063
[40]
Ramzy RM, El Setouhy M, Helmy H, Ahmed ES, Abd Elaziz KM, et al. (2006) Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment. Lancet 367: 992–999. doi: 10.1016/S0140-6736(06)68426-2
[41]
Duerr HP, Dietz K, Eichner M (2005) Determinants of the eradicability of filarial infections: a conceptual approach. Trends Parasitol 21: 88–96. doi: 10.1016/j.pt.2004.11.011
[42]
(2004) Report on the mid-term assessment of microfilaraemia reduction in sentinel sites of 13 countries of the Global Programme to Eliminate Lymphatic Filariasis. Wkly Epidemiol Rec 79: 358–365.
[43]
Weil GJ, Lammie PJ, Richards FO Jr, Eberhard ML (1991) Changes in circulating parasite antigen levels after treatment of bancroftian filariasis with diethylcarbamazine and ivermectin. J Infect Dis 164: 814–816. doi: 10.1093/infdis/164.4.814
[44]
Bockarie MJ, Tisch DJ, Kastens W, Alexander ND, Dimber Z, et al. (2002) Mass treatment to eliminate filariasis in Papua New Guinea. N Engl J Med 347: 1841–1848. doi: 10.1056/NEJMoa021309
[45]
Pedersen EM, Stolk WA, Laney SJ, Michael E (2009) The role of monitoring mosquito infection in the Global Programme to Eliminate Lymphatic Filariasis. Trends Parasitol 25: 319–327. doi: 10.1016/j.pt.2009.03.013
[46]
Bockarie MJ, Pedersen EM, White GB, Michael E (2009) Role of vector control in the global program to eliminate lymphatic filariasis. Annu Rev Entomol 54: 469–487. doi: 10.1146/annurev.ento.54.110807.090626
[47]
Simonsen PE, Meyrowitsch DW, Mukoko DA, Pedersen EM, Malecela-Lazaro MN, et al. (2004) The effect of repeated half-yearly diethylcarbamazine mass treatment on Wuchereria bancrofti infection and transmission in two East African communities with different levels of endemicity. Am J Trop Med Hyg 70: 63–71.
[48]
Dembele B, Coulibaly YI, Dolo H, Konate S, Coulibaly SY, et al. (2010) Use of high-dose, twice-yearly albendazole and ivermectin to suppress Wuchereria bancrofti microfilarial levels. Clin Infect Dis 51: 1229–1235. doi: 10.1086/657063
[49]
Pichon G (2002) Limitation and facilitation in the vectors and other aspects of the dynamics of filarial transmission: the need for vector control against Anopheles-transmitted filariasis. Ann Trop Med Parasitol 96: Suppl 2S143–152. doi: 10.1179/000349802125002509
[50]
Burkot TR, Durrheim DN, Melrose WD, Speare R, Ichimori K (2006) The argument for integrating vector control with multiple drug administration campaigns to ensure elimination of lymphatic filariasis. Filaria J 5: 10. doi: 10.1186/1475-2883-5-10
[51]
Diawara L, Traore MO, Badji A, Bissan Y, Doumbia K, et al. (2009) Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis 3: e497. doi: 10.1371/journal.pntd.0000497
[52]
Gutman J, Fagbemi A, Alphonsus K, Eigege A, Miri ES, et al. (2008) Missed treatment opportunities for schistosomiasis mansoni, in an active programme for the treatment of urinary schistosomiasis in Plateau and Nasarawa states, Nigeria. Ann Trop Med Parasitol 102: 335–346. doi: 10.1179/136485908X278810
[53]
Richards FO Jr, Eigege A, Miri ES, Jinadu MY, Hopkins DR (2006) Integration of mass drug administration programmes in Nigeria: The challenge of schistosomiasis. Bull World Health Organ 84: 673–676. doi: 10.2471/BLT.06.029652
